Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics by Yuan, Gengyang et al.
Fluorinated Adenosine A2A Receptor
Antagonists Inspired by Preladenant as
Potential Cancer Immunotherapeutics
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Yuan, G., T. C. Jankins, C. G. Patrick, P. Philbrook, O. Sears,
S. Hatfield, M. Sitkovsky, et al. 2017. “Fluorinated Adenosine
A2A Receptor Antagonists Inspired by Preladenant as Potential
Cancer Immunotherapeutics.” International Journal of Medicinal
Chemistry 2017 (1): 4852537. doi:10.1155/2017/4852537. http://
dx.doi.org/10.1155/2017/4852537.
Published Version doi:10.1155/2017/4852537
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651930
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Research Article
Fluorinated Adenosine A2A Receptor Antagonists Inspired by
Preladenant as Potential Cancer Immunotherapeutics
Gengyang Yuan,1 Tanner C. Jankins,1 Christopher G. Patrick Jr.,1 Phaethon Philbrook,2
Olivia Sears,2 Stephen Hatfield,2 Michail Sitkovsky,2 Neil Vasdev,3
Steven H. Liang,3 Mary Jo Ondrechen,1 Michael P. Pollastri,1 and Graham B. Jones1,4
1Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA
2New England Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA
3Gordon Center for Medical Imaging and Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and
Department of Radiology, Harvard Medical School, 55 Fruit St., Boston, MA 02114, USA
4Clinical and Translational Science Institute, Tufts University, 800 Washington Street, Boston, MA 02111, USA
Correspondence should be addressed to Graham B. Jones; graham.jones@tufts.edu
Received 15 May 2017; Revised 31 August 2017; Accepted 13 September 2017; Published 19 October 2017
Academic Editor: Rosaria Volpini
Copyright © 2017 Gengyang Yuan et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Antagonism of the adenosine A2A receptor on T cells blocks the hypoxia-adenosinergic pathway to promote tumor rejection.
Using an in vivo immunoassay based on the Concanavalin A mouse model, a series of A2A antagonists were studied and identified
preladenant as a potent lead compound for development. Molecular modeling was employed to assist drug design and subsequent
synthesis of analogs and those of tozadenant, including fluorinated polyethylene glycol PEGylated derivatives. The efficacy of the
analogs was evaluated using two in vitro functional bioassays, and compound 29, a fluorinated triethylene glycol derivative of
preladenant, was confirmed as a potential immunotherapeutic agent.
1. Introduction
The adenosine receptors belong to the G protein-coupled
receptor (GPCR) family including A1, A2A, A2B, and A3,
four subtypes based on their different subcellular localiza-
tion, signal transduction pathways, activation profiles, ligand
binding profiles, and G protein binding preferences [1, 2].
Adenosine receptor coupling and subsequent dissociation
with Gi and Gs proteins serve to regulate the level of adeny-
late cyclase activity, thus controlling levels of intracellular
cAMP, a second messenger known to trigger a complex
sequence of cellular events [1–3]. As a consequence, A2AR
has become a drug discovery target of increased interest,
implicated in diseases such as neurodegenerative disorders
(e.g., Parkinson’s disease), cardiac ischemia, inflammation,
and cancer [4–6]. After over a decade of effort applied
to xanthine based A2AR antagonists, a derivative KW-6002
(istradefylline, 2) was developed and approved in 2013 as
an anti-Parkinson drug in Japan under the brand name
Nouriast. The molecule preladenant (4) completed Phase
II clinical trials for Parkinson’s disease but failed to show
efficacy in subsequent Phase III trials. However, tozadenant
(SYN115, 5a) entered Phase III trials in 2015 for the same
indication (Figure 1) [7–9].
Given the surge in interest in A2AR antagonists, we
have focused effort on the immunomodulatory capacity of
agents. We have previously demonstrated antagonism of
the hypoxia-adenosinergic pathway, wherein hypoxia-driven
accumulation of extracellular adenosine triggered immune
suppression via A2AR activation on the surface of immune
cells [10–15]. Subsequent A2AR antagonism by ZM241385
(1) led to delayed growth of CL8-1 melanoma in mice
and increased levels of endogenous antitumor T cells [10–
15]. Derivatization of xanthine 2 led to a PEG derivative
(KW-PEG, 3), which showed enhanced properties, including
cAMP suppression and cytokine IFN-gamma restoration
[16]. Spurred by these findings we were motivated to employ
molecularmodelingmethods to design optimized derivatives
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Figure 1: Structures of selected A2AR antagonists 1–5a and A2AR agonist CGS21680 (CGS, 6).
ConA + CGS (6) ConA alone KW-PEG (3) KW6002 (2) Preladenant (4)
Figure 2: ConA-induced liver damage in C57BL/6 mice via CGS (6), 2, 3 and 4. Female C57BL/6 mice (𝑛 = 5) were first injected with A2AR
agonist CGS (6, 2mg kg−1), 2mg kg−1 2, 3, and 4 separately, and then Con A (20mg kg−1). Con A-induced liver damage evaluated at 8 h.
(PEG) of other classes of A2AR antagonists and to explore
both their immunomodulatory capacity and potential to be
converted to functional imaging agents.
2. Materials and Methods
To select lead compounds for immunotherapy application,
an in vivo Concanavalin A (ConA)-induced liver damage
assay was carried out in C57BL/6 mice through the phar-
macological activation and deactivation of A2ARs [17]. A
variety of compounds were screened including 2, 3, and 4
[10, 18, 19]. As shown in Figure 2, compound 4 imparted
the most severe immune induced liver damage and was
selected as a core structure for analog design. Fluorinated
analogs were envisioned to potentially serve as leads to
ultimately be labeled at the distal position with fluorine-18
(𝑡1/2 = 109.8min), for diagnostic imaging with positron
emission tomography (PET). A series of fluorinated PEG
groups with increasing chain lengths were proposed for
chemical modification to map the structure-activity relation-
ship (SAR). Such modifications increase both hydrophilicity
and molecular weight (MW), potentially to reduce blood-
brain barrier (BBB) penetration as predicted by the central
nervous system multiparameter optimization (MPO) score
reported by Wager et al. [20].
To locate the ideal position for PEG attachment, molec-
ular modeling was utilized based on our previously con-
structed homology model, which derived from the crystal
structure of A2AR in complex with 1 (PDB ID 3EML) and
includes a resolved EL2 cap [16, 21, 22]. This technique
employed Glide (Schro¨dinger, version 10.4, LLC, New York,
NY, 2015) extra precision (XP) docking to gain insights
into the ligand-protein binding interactions [23–26]. As
shown in Figure 3(a), 4 almost occupies the entire binding
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Figure 3: Glide XP docking results of 4 and 5a. The interacting residues of A2AR are colored grey and the H-bond is represented as a dotted
line. (a) 4 and (b) 5a renderings from YASARA [39].
pocket of A2AR and shares similar key binding interactions
as known ligand 1. Noteworthily, the methoxyethyl ether
group of 4 projects into the cytosolic solution and forms
an additional H-bond with Pro266 at the solvent-exposed
surface of the A2AR, connecting with the cytosolic solution.
Similarly, the current clinical candidate 5a also occupies a
position near the edge of the A2AR binding pocket, where
the piperidine quaternary alkyl group forms hydrophobic
interactions with Leu267 and His264 and the tertiary alcohol
group forms a hydrogen bond with Glu169 (Figure 3(b)) [27,
28]. It was thus suggested that introduction of hydrophilic
and fluorinated PEG groups at the phenolic position of
4 and the piperidine component of 5a would not impact
key binding events of their core structures as the pendant
groups would be capable of engaging in hydrogen bonds
at the termini or in the case of their chains via hydrated
networks. Accordingly, the octaethylene glycol monomethyl
ether moiety, a tolerable substituent in prior studies on
compound 2 [16] in conjunction with the phenyl-piperazine
linker inherent in 4, was introduced to 5a and syntheses
designed. In addition, synthesis of a demethylated version of
the compound (5b) was planned, as such could be a useful
intermediate for radiotracer synthesis (as either [11C]5a
via a one-step [11C]CH3I methylation or a base-promoted
coupling with an 18F-labeled short alkyl chain) at this locus.
Synthesis of reference compounds 2 and 3 was performed
using refinements of reported methods which produced
superior yields independent of scale [16]. For example,
use of a mild (AIBN/NBS promoted) route to the 8-
substituted xanthine scaffold resulted in an improvement
in yield from 22% to 56% for this key step (see experi-
mental section) [29]. Compounds 4 and 5a were synthe-
sized based on modified literature methods (Scheme 1)
[30–33], key intermediate 13 obtained from compound 7
via Vilsmeier-promoted halogenation and formylation, one-
pot cascade condensation with 2-furoic acid hydrazine (9)
and 2-hydroxyethyl hydrazine (11), Dimroth rearrangement
to effect triazole formation, and finally bromination with
POCl3/ZnBr2. The piperazine components were prepared
starting from either commercially available fragment 14 or
fluorination/activation of the known mono- or ditosylated
PEG chains (15–19) and subsequent coupling reaction with
1-(4-(4-hydroxyphenyl) piperazin-1-yl)ethan-1-one (20) and
then deacetylation prior to the final coupling reaction with
intermediate 13 to furnish 4 and the desired analogs 27–31
[30, 34].
Synthesis of 5a is illustrated in Scheme 2. The bro-
mide 32 was subjected to palladium-catalyzed coupling with
morpholine (33), stannous nitro reduction, condensation
with benzoyl isothiocyanate, bromine promoted formation
of the benzothiazole ring, and installation of the piperidine
ring through intermediate 38. Preparation of analog 40 was
achieved via coupling of 26 and 38 [31]. Direct demethy-
lation of 5a with BBr3 did not lead to the desired product
5b but instead led to decomposition and bromination of
the tertiary alcohol [34]. Likewise, l-selectride promoted
demethylation of 5a led to very poor yield of product
5b (5%) [35]. The sequence was finally realized when the
phenyl carbamate protecting group of 38was employed.With
demethylation achieved, the phenyl carbamate protecting
group (of 41) was replaced by 4-methylpiperidin-4-ol 39 to
afford desmethyl tozadenant, 5b. Full details of all experi-
mental procedures, bioassays, and molecular modeling are
described in the Supplementary Material available online at
https://doi.org/10.1155/2017/4852537.
3. Results and Discussion
Bioassay of compounds 27–31 and 40 and their parent com-
pounds (4 and 5a) was conducted using two functional assays
that evaluate A2AR binding-dependent signaling through
A2AR on the surface of T cells [16]. The first assay screens
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Scheme 1: Synthesis of 4 and its PEGylated analogs. Conditions: (a) POCl3, DMF, 78%; (b) 2-furoic acid hydrazide (9), Na2CO3, MeCN; (c)
2-hydroxyethyl hydrazine (11), 78% over 2 steps; (d) POCl3, ZnBr2, 45%; (e) (i) NaH, DMF; (ii) 6N HCl. 67% (𝑛 = 0, 21), 62% (𝑛 = 1, 22),
56% (𝑛 = 2, 23), 35% (𝑛 = 5, 24), 70% (𝑛 = 1, 25), 70% (𝑛 = 7, 26); (f) N,N-diisopropylethylamine (DIPEA), DMF, 52% (𝑛 = 0, 27), 47%
(𝑛 = 1, 28), 33% (𝑛 = 2, 29), 25% (𝑛 = 5, 30), 55% (𝑛 = 1, 4), and 25% (𝑛 = 7, 31).
compounds on the basis of their extent of inhibition of A2AR-
induced intracellular cAMP accumulation in A2AR express-
ing lymphocytes [36, 37].TheA2AR agonist, CGS21680 (CGS,
6), was used to activate A2AR. As shown in Figure 4, all of
the above compounds, except 40, were able to prevent CGS-
mediated signaling. Stronger antagonism was observed for
the preladenant-based analogs 27–29 versus the previously
evaluated compounds 2 and 3. Further increments of the PEG
chain length resulted in decreased antagonism (compounds
30 and 31). Surprisingly, 5a showed inferior antagonism to
that of compounds 2 and 3, and its derivative 40 exhibited no
suppression of intracellular cAMP accumulation.
An evaluation of the positive hits in the cAMP assay
(27–29) was carried out in silico by Glide docking to
study their binding orientation in A2AR. The docking results
confirmed the initial assumption for such analog design
(Figure 5), the core structures of 27–29 anchoring in similar
positions as 4, forming identical key binding interactions
with Asn253, Glu169, and Phe168. The installed PEG chains
interact with the residues at the edge of A2AR via hydrophobic
and H-bonding interactions.
The second immunoassay assesses secretion of the
cytokine IFN-gamma, since it is considered to be sensitive to
theA2AR signaling pathway [16]. In these assays, during T cell
receptor (TCR) activation by the CD3 ligand, C57BL/6 mice
splenocytes T cells are incubated with A2AR agonist CGS to
inhibit IFN-gamma secretion resulting from A2AR-induced
immunosuppression via intracellular cAMP. Effective A2AR
antagonists block the A2AR-activated signal, thus restoring
secretion of the cytokine to potentiate and prolong the
immune response. Compounds 29, 2, 3, and 4 were evaluated
(Figure 6), and compound 29 showed similar capacity to that
of 4, both of which resulted in superior restoration of IFN-
gamma secretion compared to either 2 or 3.
International Journal of Medicinal Chemistry 5
O
Br
N
O
O
N
N
O
O
O
N
O
N
H
S
NH
N
O
O
O
S
N
N
O
O
HN
O
PhO
S
N
N
O
O
32 34 35 36
37 38
(a) (b) (c) (d)
(e)
HN
O
PhO
S
N
N
O
OH
N
N
S
OH
O
HO O
N
HN
41 5b
(h)
5a
N
N
HN
S
O
O
O
N N O
40
(f) (g)
(i)
O
n=8
／−
／−
．（2
．（2
+
+
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Figure 4: Intracellular cAMP levels in lymphocytes after incubation with vehicle, 1 𝜇M CGS, and 1 𝜇M CGS plus 1 𝜇M of compounds 4
(preladenant), 27–31, 5a (tozadenant), 40, 2 (KW-6002), and 3 (KW-PEG) are shown.The intracellular cAMP levels were determined 15min
following stimulation using quantitative cAMP ELISA and are expressed as fmol/106 cells. Data shown represent mean ± SEM of triplicate
samples.
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(a) (b) (c)
Figure 5: Docking results of 27–29 via Glide XP method. The interacting residues of A2AR are colored grey and the H-bond is represented
as cyan dotted line. (a) Compound 27. (b) Compound 28. (c) Compound 29. Rendered from YASARA [39].
Table 1: Physicochemical properties and docking results of compounds 27–29.
Compound Glide score log𝐷7.4
Aqueous
solubility
(𝜇M)
Human PPB
(%)
HLM CLint
(𝜇L/min/mg)
Rat
hepatocyte
CLint
(𝜇L/min/106)
27 −12.2 2.8 74 99 16.5 29.9
28 −11.8 2.5 2 98.7 71.9 12.8
29 −12.3 2.3 10 98.3 66.1 72.9
∗
∗∗ NS
∗p < 0.01
∗∗p < 0.001
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Figure 6: The IFN-gamma production by splenocytes after acti-
vation with 0.1 𝜇g/mL anti-CD3 and when treated with vehicle,
1 𝜇M CGS, and 1𝜇M CGS plus 1 𝜇M compounds 29, 2 (KW-6002),
3 (KW-PEG), and 4 (preladenant) separately is shown. The IFN-
gamma levels were determined in the supernatant one day following
stimulation using quantitative ELISA and are expressed as pg/mL.
Data shown represent mean ± SEM of triplicate samples.
Given the promising results in functional assays,
the physicochemical properties of compound 29 and
its homologs were determined, including its log𝐷7.4,
aqueous solubility, human plasma protein binding (PPB),
and metabolic stability [human liver microsome and rat
hepatocyte clearance] as shown in Table 1. Broadly similar
results were obtained, principle differences being enhanced
aqueous solubility for 27, whereas intrinsic clearance was
superior for 29 in the rodent derived line and for 28 in the
human cell line. Reduced clearance for 27 in turn may bode
well for use in biodistribution studies [38].
4. Conclusions
In summary, we have designed and synthesized a family of
PEGylated analogs of 4 and 5a using molecular modeling
techniques. Lead compound 29, a fluorinated triethylene
glycol derivative of preladenant, was identified, which shows
promising results in two functional immunoassays and
physicochemical assays. Future work will focus on detailed
mechanistic studies on the mode of action of 29 and inves-
tigation of its use as a potential cancer immunotherapeutic
agent.
International Journal of Medicinal Chemistry 7
Conflicts of Interest
The authors report no conflicts of interest.
Acknowledgments
This research was supported by Northeastern University
and by grants from the National Institutes of Health
(UL1TR001064 and CA111985-04) and National Science
Foundation (MCB-1517290 and CHE-1305655). The authors
are grateful to AstraZeneca for obtaining the measured
physicochemical properties of 27–29 and Dr. Xi-Ping Huang
for helpful discussions. Steven H. Liang is a recipient of NIH
career development award from the National Institute on
Drug Abuse (DA038000).
References
[1] K.A. Jacobson andZ.G.Gao, “Adenosine receptors as therapeu-
tic targets,” Nature Reviews Drug Discovery, vol. 5, pp. 247–264,
2006.
[2] S. Moro, Z.-G. Gao, K. A. Jacobson, and G. Spalluto, “Progress
in the pursuit of therapeutic adenosine receptor antagonists,”
Medicinal Research Reviews, vol. 26, no. 2, pp. 131–159, 2006.
[3] M. Congreve, C. J. Langmead, J. S. Mason, and F. H. Marshall,
“Progress in structure based drug design for G protein-coupled
receptors,” Journal of Medicinal Chemistry, vol. 54, no. 13, pp.
4283–4311, 2011.
[4] A. Bilkei-Gorzo, O. M. Abo-Salem, A. M. Hayallah, K. Michel,
C. E. Mu¨ller, and A. Zimmer, “Adenosine receptor subtype-
selective antagonists in inflammation and hyperalgesia,” Nau-
nyn-Schmiedeberg’s Archives of Pharmacology, vol. 377, no. 1, pp.
65–76, 2008.
[5] S. Redenti, A. Ciancetta, G. Pastorin et al., “Pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidines and structurally simplified
analogs. Chemistry and SAR profile as adenosine receptor
antagonists,” Current Topics in Medicinal Chemistry, vol. 16, no.
28, pp. 3224–3257, 2016.
[6] A. El Maatougui, J. Azuaje, M. Gonza´lez-Go´mez et al., “Dis-
covery of potent and highly selective A2B adenosine receptor
antagonist chemotypes,” Journal ofMedicinal Chemistry, vol. 59,
no. 5, pp. 1967–1983, 2016.
[7] M. de Lera Ruiz, Y. H. Lim, and J. Zheng, “Adenosine A2A
receptor as a drug discovery target,” Journal of Medicinal
Chemistry, vol. 57, no. 9, pp. 3623–3650, 2014.
[8] G. Yuan, N. G. Gedeon, T. C. Jankins, and G. B. Jones, “Novel
approaches for targeting the adenosine A2A receptor,” Expert
Opinion on Drug Discovery, vol. 10, no. 1, pp. 63–80, 2015.
[9] G. Yuan and G. B. Jones, “Towards next generation adenosine
A2A receptor antagonists,”CurrentMedicinal Chemistry, vol. 21,
p. 3918, 2014.
[10] A. Chouker, M. Thiel, D. Lukashev et al., “Critical role of
hypoxia and A2A adenosine receptors in liver tissue-protecting
physiological anti-inflammatory pathway,”Molecular Medicine,
vol. 14, p. 116, 2008.
[11] D. Lukashev, A. Ohta, and M. Sitkovsky, “Hypoxia-dependent
anti-inflammatory pathways in protection of cancerous tissues,”
Cancer andMetastasis Reviews, vol. 26, no. 2, pp. 273–279, 2007.
[12] D. Lukashev, M. Sitkovsky, and A. Ohta, “From “Hell-
strom paradox” to anti-adenosinergic cancer immunotherapy,”
Purinergic Signalling, vol. 3, no. 1-2, pp. 129–134, 2007.
[13] M. Sitkovsky, D. Lukashev, S. Deaglio, K. Dwyer, S. C. Robson,
and A. Ohta, “Adenosine A2A receptor antagonists: blockade of
adenosinergic effects and T regulatory cells,” British Journal of
Pharmacology, vol. 153, no. 1, pp. S457–S464, 2008.
[14] M. V. Sitkovsky, “T regulatory cells: hypoxia-adenosinergic
suppression and re-direction of the immune response,” Trends
in Immunology, vol. 30, no. 3, pp. 102–108, 2009.
[15] M. V. Sitkovsky, J. Kjaergaard, D. Lukashev, and A. Ohta,
“Hypoxia-adenosinergic immunosuppression: Tumor protec-
tion by T regulatory cells and cancerous tissue hypoxia,”Clinical
Cancer Research, vol. 14, no. 19, pp. 5947–5952, 2008.
[16] R. Thomas, J. Lee, V. Chevalier et al., “Design and evaluation
of xanthine based adenosine receptor antagonists: Potential
hypoxia targeted immunotherapies,” Bioorganic & Medicinal
Chemistry, vol. 21, no. 23, pp. 7453–7464, 2013.
[17] A. Ohta and M. Sitkovsky, “Role of G-protein-coupled adeno-
sine receptors in downregulation of inflammation and protec-
tion from tissue damage,” Nature, vol. 414, no. 6866, pp. 916–
920, 2001.
[18] R. A.Hodgson, R. Bertorelli, G. B. Varty et al., “Characterization
of the potent and highly selective A2A receptor antagonists
preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-
piperazinyl]ethyl]-2-(2-furanyl)-7hpyrazolo[ 4,3-e][1,2,4]tria-
zolo[1,5-c] pyrimidin-5-amine in rodent models of movement
disorders and depression,” The Journal of Pharmacology and
Experimental Therapeutics, vol. 330, no. 1, pp. 294–303, 2009.
[19] R. A. Hauser, F. Stocchi, O. Rascol et al., “Preladenant as an
adjunctive therapywith levodopa in Parkinsondisease: two ran-
domized clinical trials and lessons learned,” JAMA Neurology,
vol. 72, no. 12, pp. 1491–1500, 2015.
[20] T. T. Wager, X. Hou, P. R. Verhoest, and A. Villalobos, ACS
Chem. Neurosci, vol. 1, p. 435, 2010.
[21] V.-P. Jaakola, M. T. Griffith, M. A. Hanson et al., “The 2.6
angstrom crystal structure of a human A2A adenosine receptor
bound to an antagonist,” Science, vol. 322, no. 5905, pp. 1211–1217,
2008.
[22] H. Piirainen, Y. Ashok, R. T. Nanekar, and V.-P. Jaakola, “Struc-
tural features of adenosine receptors: from crystal to function,”
Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1808,
no. 5, pp. 1233–1244, 2011.
[23] R. A. Friesner, R. B. Murphy, M. P. Repasky et al., “Extra
precision glide: Docking and scoring incorporating a model of
hydrophobic enclosure for protein-ligand complexes,” Journal
of Medicinal Chemistry, vol. 49, no. 21, pp. 6177–6196, 2006.
[24] R. A. Friesner, J. L. Banks, R. B. Murphy et al., “Glide: a new
approach for rapid, accurate docking and scoring. 1. Method
and assessment of docking accuracy,” Journal of Medicinal
Chemistry, vol. 47, no. 7, pp. 1739–1749, 2004.
[25] T. A. Halgren, R. B. Murphy, R. A. Friesner et al., “Glide: a new
approach for rapid, accurate docking and scoring. 2. Enrich-
ment factors in database screening,” Journal ofMedicinal Chem-
istry, vol. 47, no. 7, pp. 1750–1759, 2004.
[26] D. Shivakumar, J. Williams, Y. Wu,W. Damm, J. Shelley, andW.
Sherman, “Prediction of absolute solvation free energies using
molecular dynamics free energy perturbation and the opls force
field,” Journal of Chemical Theory and Computation, vol. 6, no.
5, pp. 1509–1519, 2010.
[27] R. A. Hauser, C. W. Olanow, K. D. Kieburtz et al., “Tozadenant
(SYN115) in patients with Parkinson’s disease who have motor
fluctuations on levodopa: A phase 2b, double-blind, ran-
domised trial,”The Lancet Neurology, vol. 13, no. 8, pp. 767–776,
2014.
8 International Journal of Medicinal Chemistry
[28] Biotie Therapies: Biotie announces start of tozadenant Phase 3
Study in Parkinson’s disease. Press Release, July 21, 2015.
[29] P. Bandyopadhyay, S. K. Agrawal,M. Sathe, P. Sharma, andM. P.
Kaushik, “A facile and rapid one-step synthesis of 8-substituted
xanthine derivatives via tandem ring closure at room tempera-
ture,” Tetrahedron, vol. 68, no. 20, pp. 3822–3827, 2012.
[30] S. C. Kuo, L. T. Tran, and P. Zhang, WO054245 A3.
[31] A. Flohr, J. L. Moreau, S. Poli, C. Riemer, and L. Steward,
US20050261289 A1.
[32] E. Marom, M. Mizhiritskii, and S. Rubnov, WO2012127472 A1.
[33] C. Vala, T. J. Morley, X. Zhang et al., “Synthesis and in vivo
Evaluation of Fluorine-18 and Iodine-123 Pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidine Derivatives as PET and SPECT
Radiotracers forMappingA2AReceptors,”ChemMedChem, pp.
1936–1943, 2016.
[34] M. Cui, M. Ono, H. Kimura et al., “Novel 18F-labeled ben-
zoxazole derivatives as potential positron emission tomography
probes for imaging of cerebral 𝛽-amyloid plaques in alzheimers
disease,” Journal of Medicinal Chemistry, vol. 55, no. 21, pp.
9136–9145, 2012.
[35] A. Coop and K. C. Rice, US6395900 B1.
[36] A. Ohta, E. Gorelik, S. J. Prasad et al., “A2A adenosine receptor
protects tumors from antitumor T cells,” Proceedings of the
National Acadamy of Sciences of the United States of America,
vol. 103, no. 35, pp. 13132–13137, 2006.
[37] S. Apasov, J. F. Chen, P. Smith, and M. Sitkovsky, “A2A receptor
dependent and A2A receptor independent effects of extracellu-
lar adenosine onmurine thymocytes in conditions of adenosine
deaminase deficiency,” Blood, vol. 95, 3859 pages, 2000.
[38] O. Barret, J. Hannestad, C. Vala et al., “Characterization in
humans of 18F-MNI-444, a PET radiotracer for brain adenosine
2A receptors,” Journal of Nuclear Medicine, vol. 56, no. 4, pp.
586–591, 2015.
[39] E. Krieger and G. Vriend, “YASARA view—molecular graphics
for all devices—from smartphones to workstations,” Bioinfor-
matics, vol. 30, no. 20, pp. 2981-2982, 2014.
